Early antibody treatment, inflammation, and risk of post-COVID conditions.
Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Bloch EM, Hanley D, Casadevall A, Tobian AAR, Sullivan DJ; CSSC-004 Consortium.
Gebo KA, et al. Among authors: zhu x.
mBio. 2023 Oct 31;14(5):e0061823. doi: 10.1128/mbio.00618-23. Epub 2023 Sep 19.
mBio. 2023.
PMID: 37724870
Free PMC article.
Clinical Trial.